Bifogade filer
Cantargia to Participate in Upcoming Conferences
Kurs
-2,09%
Likviditet
4,80 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-20 | 07:00 | Bokslutskommuniké 2025 |
| 2025-11-19 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2025-05-15 | - | Årsstämma |
| 2025-05-13 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-21 | - | Bokslutskommuniké 2024 |
| 2024-12-02 | - | Extra Bolagsstämma 2025 |
| 2024-11-15 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-24 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-05-21 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-22 | - | Bokslutskommuniké 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-24 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2023-05-23 | - | Årsstämma |
| 2023-05-23 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-30 | - | Kvartalsrapport 2022-Q2 |
| 2022-07-21 | - | Extra Bolagsstämma 2022 |
| 2022-05-24 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2022-05-23 | - | Årsstämma |
| 2022-05-23 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-13 | - | Extra Bolagsstämma 2020 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-28 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2020-05-27 | - | Årsstämma |
| 2020-05-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-28 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2019-05-27 | - | Årsstämma |
| 2019-05-27 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-27 | - | Bokslutskommuniké 2018 |
| 2018-11-15 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-01 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2018-05-31 | - | Årsstämma |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-15 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-31 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2017-05-30 | - | Årsstämma |
| 2017-05-15 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-15 | - | Bokslutskommuniké 2016 |
| 2017-01-16 | - | Extra Bolagsstämma 2017 |
| 2016-11-21 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-25 | - | Årsstämma |
| 2016-05-16 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-02 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
| 2016-03-01 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-25 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-19 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-03 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced that management will participate in the following investor conferences.
Stifel 2025 Healthcare Conference, New York City
Presentation by Hilde Steineger, CEO.
November 12 at 11.20 am ET (17.20pm CET).
DnB Carnegie Nordic Healthcare Conference, Oslo
Presentation by Hilde Steineger, CEO
November 25, exact time is to be confirmed.
Live webcasts and replays, when available, can be found under the Newsroom section on Cantargia’s homepage at https://cantargia.com. The archived webcast will be available for replay for at least 30 days.
For further information, please contact
Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: info@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.